Perioperative Durvalumab + FLOT Improves Survival in Resectable Gastric Cancer – The Babak Lab
The Babak Lab shared a recent article by Yelena Janjigian et al, on LinkedIn, adding:
“Clinical Mondays: Perioperative Durvalumab + FLOT Improves Survival in Resectable Gastric Cancer
A phase 3 MATTERHORN trial, published in NEJM (June 1, 2025), demonstrates that adding durvalumab to perioperative FLOT chemotherapy significantly improves event‑free survival in patients with resectable gastric or gastroesophageal junction adenocarcinoma.
Study Focus:
Compare standard perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) alone versus FLOT + durvalumab (1500 mg every 4 weeks before and after surgery) in operable disease.
Experimental Highlights:
- Randomized, double-blind, placebo-controlled phase 3 MATTERHORN with 948 patients
- Median follow-up ~31.5 months
- 2‑year event‑free survival (EFS): 67.4% with durvalumab vs 58.5% with placebo; HR 0.71 (95% CI 0.58–0.86; p < 0.001)
- 2‑year overall survival: 75.7% vs 70.4% (HR 0.67 after 12 months; p = 0.03)
- Pathologic complete response: 19.2% vs 7.2% (RR 2.69)
- Grade 3–4 adverse events: 71.6% vs 71.2%; surgery delays and initiation of adjuvant therapy similar
Key Findings:
- Adding durvalumab to perioperative chemotherapy improves EFS and OS
- Pathologic complete response rates nearly triple
- Safety profile comparable between arms
Conclusion:
Perioperative durvalumab + FLOT offers a new standard of care for resectable gastric and gastroesophageal junction adenocarcinoma, reducing recurrence and potentially enhancing cure rates.
Image generated using Sora by OpenAI.”
Title: Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
Authors: Yelena Janjigian, Salah-Eddin Al-Batran, Zev Wainberg, Kei Muro, Daniela Molena, Eric Van Cutsem, Woo Jin Hyung, Lucjan Wyrwicz, Do-Youn Oh, Takeshi Omori, Markus Moehler, Marcelo Garrido, Sulene Oliveira, Moishe Liberman, Victor Castro Oliden, Elizabeth Smyth, Alexander Stein, Mehmet Bilici, Maria Alvarenga, Vadim Kozlov, Fernando Rivera, Akihito Kawazoe, Olivier Serrano, Eric Heilbron, Alejandra Negro, John Kurland, Josep Tabernero
Read the Full Article on NEJM
More posts featuring The Babak Lab.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023